Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: Involvement of lactic acid

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 297, Issue 3, 2009, Pages

  Watanabe, Toshio ^a   Nishio, Hikaru ^b   Tanigawa, Tetsuya ^a   Yamagami, Hirokazu ^a   Okazaki, Hirotoshi ^a   Watanabe, Kenji ^a   Tominaga, Kazunari ^a   Fujiwara, Yasuhiro ^a   Oshitani, Nobuhide ^a   Asahara, Takashi ^c   Nomoto, Koji ^c   Higuchi, Kazuhide ^d   Takeuchi, Koji ^b   Arakawa, Tetsuo ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^c YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^d OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Enteropathy; Signal transduction; Toll like receptor

Indexed keywords

I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; LACTIC ACID; LIPOPOLYSACCHARIDE; MESSENGER RNA; MYELOPEROXIDASE; PROBIOTIC AGENT; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GRAM NEGATIVE BACTERIUM; HUMAN; HUMAN CELL; INTESTINE INJURY; LACTOBACILLUS CASEI; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SUPERNATANT; WESTERN BLOTTING;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; HUMANS; I-KAPPA B PROTEINS; INDOMETHACIN; INTESTINAL DISEASES; INTESTINE, SMALL; LACTIC ACID; LACTOBACILLUS CASEI; MALE; MONOCYTES; NF-KAPPA B; PEROXIDASE; PHOSPHORYLATION; PROBIOTICS; RATS; RATS, WISTAR; RNA, MESSENGER; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 69749099183     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.90553.2008     Document Type: Article

References (34)

1. Asahara T, Nomoto K, Shimizu K, Watanuki M, Tanaka R. Increased resistance of mice to Salmonella enterica serovar Typhimurium infection by synbiotic administration of Bifidobacteria and transgalactosylated oligosaccharides. J Appl Microbiol 91: 985-996, 2001. (Pubitemid 33132065)
2. Asahara T, Nomoto K, Watanuki M, Yokokura T. Antimicrobial activity of intraurethrally administered probiotic Lactobacillus casei in a murine model of Escherichia coli urinary tract infection. Antimicrob Agents Chemother 45: 1751-1760, 2001. (Pubitemid 32466345)
3. Baeuerle PA, Baltimore D. I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 242: 540-546, 1988. (Pubitemid 18263193)
4. Baldwin AS Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest 107: 3-6, 2001.
5. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100: 1539-1546, 2005. (Pubitemid 41032360)
6. Douvdevani A, Abramson O, Tamir A, Konforty A, Isakov N, Chaimovitz C. Commercial dialysate inhibits TNF alpha mRNA expression and NF-kappa B DNA-binding activity in LPS-stimulated macrophages. Kidney Int 47: 1537-1545, 1995.
7. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl: S81-S96, 2002. (Pubitemid 34457854)
8. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 3: 133-141, 2005. (Pubitemid 40220308)
9. Hawkey CJ, Ell C, Simon B, Albert J, Keuchel M, McAlindon M, Fortun P, Schumann S, Bolten W, Shonde A, Hugot JL, Yu V, Arulmani U, Krammer G, Rebuli R, Toth E. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clin Gastroenterol Hepatol 6: 536-544, 2008.
10. Hutt P, Shchepetova J, Loivukene K, Kullisaar T, Mikelsaar M. Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens. J Appl Microbiol 100: 1324-1332, 2006. (Pubitemid 43725697)
11. Jensen JC, Buresh C, Norton JA. Lactic acidosis increases tumor necrosis factor secretion and transcription in vitro. J Surg Res 49: 350-353, 1990. (Pubitemid 20361598)
12. Kawai T, Akira S. TLR signaling. Cell Death Differ 13: 816-825, 2006.
13. Kellum JA, Song M, Li J. Lactic and hydrochloric acids induce different patterns of inflammatory response in LPS-stimulated RAW 264.7 cells. Am J Physiol Regul Integr Comp Physiol 286: R686-R692, 2004. (Pubitemid 38374999)
14. Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282: 1929-1933, 1999.
15. Maiden L, Thjodleifsson B, Seigal A, Bjarnason II, Scott D, Birgisson S, Bjarnason I. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol 5: 1040-1045, 2007.
16. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 128: 1172-1178, 2005.
17. Matsumoto S, Hara T, Hori T, Mitsuyama K, Nagaoka M, Tomiyasu N, Suzuki A, Sata M. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the downregulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol 140: 417-426, 2005. (Pubitemid 40813951)
18. Matsuzaki T. Immunomodulation by treatment with Lactobacillus casei strain Shirota. Int J Food Microbiol 41: 133-140, 1998. (Pubitemid 28369427)
19. Miyake K. Innate recognition of lipopolysaccharide by CD14 and toll-like receptor 4-MD-2: unique roles for MD-2. Int Immunopharmacol 3: 119-128, 2003. (Pubitemid 36106457)
20. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, Kitamura T, Kosugi A, Kimoto M, Miyake K. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol 3: 667-672, 2002. (Pubitemid 34752476)
21. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EMM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128: 541-551, 2005.
22. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282: 2085-2088, 1998. (Pubitemid 29001265)
23. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon AT. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354: 635-639, 1999. (Pubitemid 29391428)
24. Schurr A, Payne RS, Miller JJ, Rigor BM. Brain lactate, not glucose, fuels the recovery of synaptic function from hypoxia upon reoxygenation: an in vitro study. Brain Res 744: 105-111, 1997. (Pubitemid 27033584)
25. Schurr A, Payne RS, Miller JJ, Tseng MT, Rigor BM. Blockade of lactate transport exacerbates delayed neuronal damage in a rat model of cerebral ischemia. Brain Res 895: 268-272, 2001. (Pubitemid 32231167)
26. Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol Rev 28: 405-440, 2004.
27. Sgouras D, Maragkoudakis P, Petraki K, Martinez-Gonzalez B, Eriotou E, Michopoulos S, Kalantzopoulos G, Tsakalidou E, Mentis A. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol 70: 518-526, 2004. (Pubitemid 38090245)
28. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284: 1247-1255, 2000.
29. Tien MT, Girardin SE, Regnault B, Le Bourhis L, Dillies MA, Coppee JY, Bourdet-Sicard R, Sansonetti PJ, Pedron T. Anti-inflammatory effect of Lactobacillus casei on Shigella-infected human intestinal epithelial cells. J Immunol 176: 1228-1237, 2006. (Pubitemid 43099727)
30. Watanabe T, Higuchi K, Hamaguchi M, Shiba M, Tominaga K, Fujiwara Y, Matsumoto T, Arakawa T. Monocyte chemotactic protein- 1 regulates leukocyte recruitment during gastric ulcer recurrence induced by tumor necrosis factor-α. Am J Physiol Gastrointest Liver Physiol 287: G919-G928, 2004. (Pubitemid 39280450)
31. Watanabe T, Higuchi K, Kobata A, Nishio H, Tanigawa T, Shiba M, Tominaga K, Fujiwara Y, Oshitani N, Asahara T, Nomoto K, Takeuchi K, Arakawa T. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 57: 181-187, 2008. (Pubitemid 351158044)
32. Watanabe T, Sugimori S, Kameda N, Machida H, Okazaki H, Tanigawa T, Watanabe K, Tominaga K, Fujiwara Y, Oshitani N, Higuchi K, Arakawa T. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 6: 1279-1282, 2008.
33. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, Swannell AJ, Hawkey CJ. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338: 719-726, 1998.
34. Yuki N, Watanabe K, Mike A, Tagami Y, Tanaka R, Ohwaki M, Morotomi M. Survival of a probiotic, Lactobacillus casei strain Shirota, in the gastrointestinal tract: selective isolation from faeces and identification using monoclonal antibodies. Int J Food Microbiol 48: 51-57, 1999. (Pubitemid 29249296)